Previous close | 7.08 |
Open | 8.71 |
Bid | 7.02 x 200 |
Ask | 7.05 x 200 |
Day's range | 6.79 - 8.71 |
52-week range | 5.70 - 13.32 |
Volume | |
Avg. volume | 1,236,935 |
Market cap | 934.504M |
Beta (5Y monthly) | 1.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Relay Therapeutics ( NASDAQ:RLAY ) First Quarter 2024 Results Key Financial Results Revenue: US$10.0m (up by US$9.78m...
Despite Net Loss, Relay Therapeutics Reports Significant Revenue Growth and Robust Pipeline Progress
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 11.43% and 2,905.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?